NPC @ ISPOR 22nd Annual International Meeting

  • May 20, 9:00am - May 24 5:00pm, 2017
NPC logo

Join NPC at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting in Boston, Massachusetts, on May 20-24. NPC will participate in issue panels, workshops and poster presentations throughout the conference featuring Vice President of Comparative Effectiveness Research Jennifer Graff, PharmD; Vice President of Research Michael Ciarametaro, MBA; University of Southern California Schaeffer-NPC Postdoctoral Health Policy Fellow Ilene Hollin, PhD; and Research Associate Lisabeth Buelt, MPH, including:

  • Value Assessment Debate: Pluralistic Approach or Does One Size Fit All?
  • Is There Consistency in the Evidence That Payers Report Reviewing When Determining Drug Coverage? Should it be Consistent?
  • Actuarial and Health Economic Approaches to Assess Value: Speaking the Same Language or Need for Translation?
  • Health Care Economic Information: Considerations for Expanding Proactive Communications by Biopharmaceutical Manufacturers to Population Health Decision-makers
  • Will the Revised HHS Risk Adjustment Methodology Improve Accuracy in Predicting Costs for Diseases with Non-Uniform Patient Use of Specialty Therapeutics?

Join us for presentations, workshops and more, and be sure to stop by the NPC table at Booth 411 to learn about our latest research and activities.

Sessions

IP3: VALUE ASSESSMENT DEBATE: PLURALISTIC APPROACH OR DOES ONE SIZE FIT ALL?
Monday, May 22, 11 a.m.-12 p.m.

Moderator: Mike Ciarametaro, MBA, Vice President, NPC

Panelists:

  • Ilene L. Hollin, PhD, MPH, Health Policy Fellow, NPC and University of Southern California Schaeffer Center for Health Policy and Economics
  • Michael S. Sherman, MD, MBA, MS, Senior Vice President & Chief Medical Officer, Harvard Pilgrim Health Care
  • Eleanor M. Perfetto, PhD, RPh, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, USA and Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy

W2: ACTUARIAL AND HEALTH ECONOMIC APPROACHES TO ASSESS VALUE: SPEAKING THE SAME LANGUAGE OR NEED FOR TRANSLATION?
Monday, May 22, 2:15 p.m.-3:15 p.m.

Discussion Leaders:

  • Jennifer S. Graff, PharmD, Vice President, NPC
  • Gabriela Dieguez, FSA, MAAA, Principal and Consulting Actuary, Milliman
  • Darius Lakdawalla, PhD, Professor, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, University of Southern California
  • Karl J. Gregor, PharmD, MS, Managing Director, Actuarial Consulting, Optum

IP6: IS THERE CONSISTENCY IN THE EVIDENCE THAT PAYERS REPORT REVIEWING WHEN DETERMINING DRUG COVERAGE? SHOULD IT BE CONSISTENT?
Monday, May 22, 3:45 p.m.- 4:45 p.m.

Moderator: Jennifer S. Graff, PharmD, Vice President, NPC

Panelists:

  • Jessica Daw, PharmD, MBA, Director, Clinical Pharmacy, UPMC Health Plan
  • Newell McElwee, PharmD, MSPH, Vice President, Health Economics and Outcomes Research, Boehringer-Ingelheim
  • James D. Chambers, PhD, MPharm, MSc, Assistant Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center

Poster Presentation: WILL THE REVISED HHS RISK ADJUSTMENT METHODOLOGY IMPROVE ACCURACY IN PREDICTING COSTS FOR DISEASES WITH NON-UNIFORM PATIENT USE OF SPECIALTY THERAPEUTICS?
Monday, May 22, 8:30 a.m.-2:30 p.m.

Presented by: Lisabeth Buelt, MPH, Research Associate, NPC

Poster by:

  • Lisabeth Buelt, MPH, Research Associate, NPC
  • Mike Ciarametaro, MBA, Vice President, NPC
  • Robert W. Dubois, MD, PhD, Chief Science Officer and Executive Vice President, NPC

IP14: HEALTH CARE ECONOMIC INFORMATION: CONSIDERATIONS FOR EXPANDING PROACTIVE COMMUNICATIONS BY BIOPHARMACEUTICAL MANUFACTURERS TO POPULATION HEALTH DECISION MAKERS (Invited Issue Panel)
Tuesday, May 23, 3:45 p.m.-4:45 p.m.

Moderator: Soumi Saha, PharmD, JD, Assistant Director of Pharmacy and Regulatory Affairs, Academy of Managed Care Pharmacy

Panelists:

  • Jennifer S. Graff, PharmD, Vice President, NPC
  • Joe Vandigo, MS, MBA, Director, Policy & Research, Pharmaceutical Research and Manufacturers of America (PhRMA)